Novo Nordisk (NOVOB DC) says there are stable Ozempic supplies across Canada

The distinction that matters is what stability implies for the compounding channel: in jurisdictions where copycat versions have been tolerated only while the originator product is formally in shortage, a declaration of adequate supply is typically the precursor to that grey market being shut down, shifting volume back to the branded product at full price. Company assurances of this sort have historically preceded rather than followed regulator action, so the tell is whether the relevant drug supply databases are updated to reflect normal availability. For the equity read, precedent in this franchise has been that capacity and supply headlines move the shares more than demand data does, since the constraint on growth has been manufacturing throughput rather than prescription trends. Worth watching is whether the assurance extends to other markets or remains Canada-specific, and whether the competitive peer set issues parallel statements, as staggered supply normalisation across the duopoly has tended to determine relative share performance.